Evaluation of the " Tele-follow-up " for the Follow-up of Implantable Defibrillators

NCT ID: NCT00598026

Last Updated: 2023-05-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1501 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-14

Study Completion Date

2011-03-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The implantable cardioverter defibrillator (ICD) has been shown to be effective in preventing mortality in patients with ventricular tachyarrhythmia. However, the expanding indications of this therapy will have an impact on the follow-up policy. Currently, regular follow-up visits are scheduled every 3 months. In this context, the recently-introduced "remote monitoring" devices constitute a promising new technique, allowing to transmit information about the status of the device and ICD therapies, without direct contact between patients and physicians. This monitoring by "tele-follow-up" might reduce the cost of care by avoiding useless visits to the implantation centre.

The aim of our study is to assess the cost-benefit ratio of "tele-follow-up" assisted care as compared with the conventional ICD follow-up.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The implantable cardioverter defibrillator (ICD) has been shown to be effective in preventing mortality in patients with ventricular tachyarrhythmia. However, the expanding indications of this therapy will have an impact on the follow-up policy. Currently, regular follow-up visits are scheduled every 3 months. In this context, the recently-introduced "remote monitoring" devices constitute a promising new technique, allowing to transmit information about the status of the device and ICD therapies, without direct contact between patients and physicians. This monitoring by "tele-follow-up" might reduce the cost of care by avoiding useless visits to the implantation centre.

The aim of our study is to assess the cost-benefit ratio of "tele-follow-up" assisted care as compared with the conventional ICD follow-up. Thanks to an open label, randomized, 2 arms study : one using a telephone follow up, the other a conventional follow-up.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Defibrillators, Implantable Telemedicine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Tele- follow-up: remote transmission to the implantation centre every 3 months

Group Type EXPERIMENTAL

Tele- follow-up

Intervention Type OTHER

Remote transmission to the implantation centre every 3 months

2

Conventional follow-up: visits at the implantation centre every 3 months

Group Type ACTIVE_COMPARATOR

Conventional follow-up

Intervention Type OTHER

Visits at the implantation centre every 3 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tele- follow-up

Remote transmission to the implantation centre every 3 months

Intervention Type OTHER

Conventional follow-up

Visits at the implantation centre every 3 months

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults over 18,
* First implantation of an implantable cardioverter defibrillator device (CRT-D devices being excluded), single or dual-chamber in primary or secondary prevention,
* ICD with data-transmission features,
* GSM mobile phone network at patient home compatible with remote transmission,
* Patient able to use correctly the transmission system,
* Patients having given a written informed consent.

Exclusion Criteria

* Class IV of NYHA,
* Concomitant pathology leading to a life expectancy inferior to the protocol duration,
* Concomitant participation to another protocol.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, France

OTHER_GOV

Sponsor Role collaborator

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe MABO, MD, PhD

Role: STUDY_DIRECTOR

Rennes University Hospital

Eric BELLISSANT, MD, PhD

Role: STUDY_CHAIR

Rennes University Hospital

Isabelle DURAND-ZALESKI, MD, PhD

Role: STUDY_CHAIR

Creteil University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Cardiologie - Centre Hospitalier du Pays d'Aix

Aix-en-Provence, , France

Site Status

Service de Cardiologie - CHU d'Angers

Angers, , France

Site Status

Service de Cardiologie - CHU Jean Minjoz

Besançon, , France

Site Status

Service de Cardiologie -Hôpital de la Cavale Blanche

Brest, , France

Site Status

Service de Cardiologie - Groupement Hospitalier Est de Lyon

Bron, , France

Site Status

Service de Cardiologie - Hôpital de la Côte de Nacre

Caen, , France

Site Status

Service de Cardiologie - CHU de Clermont-Ferrand

Clermont-Ferrand, , France

Site Status

Service de Cardiologie - Hôpital Henri Mondor

Créteil, , France

Site Status

Centre de Cardiologie - CHU de Dijon

Dijon, , France

Site Status

Service de cardiologie et Urgences cardiologiques - Hôpital Michallon

Grenoble, , France

Site Status

Cardiologie A - CHRU de Lille

Lille, , France

Site Status

Service de Cardiologie - CHU de Limoges

Limoges, , France

Site Status

Service de Cardiologie - CHU Timone Adultes

Marseille, , France

Site Status

Département de Cardiologie - CHU de Montpellier

Montpellier, , France

Site Status

Service de Cardiologie - Institut du Thorax - Hôpital Laennec

Nantes, , France

Site Status

Service de Cardiologie - Hôpital Pasteur

Nice, , France

Site Status

Service de Cardiologie - CHU de Nîmes

Nîmes, , France

Site Status

Service de Cardiologie - Hôpital Européen Georges Pompidou

Paris, , France

Site Status

Service de Cardiologie - Hôpital Lariboisière

Paris, , France

Site Status

Institut de Cardiologie - Hôpital de la Pitité Salpétrière

Paris, , France

Site Status

Hôpital Cardiologique du Haut Lévêque - CHU de Bordeaux

Pessac, , France

Site Status

Service médico-chirurgical de Cardiologie - CHU de Poitiers

Poitiers, , France

Site Status

Département de Cardiologie - CHU de Reims

Reims, , France

Site Status

Département de Cardiologie et Maladies Vasculaires - Hôpital de Pontchaillou

Rennes, , France

Site Status

Service de Cardiologie - Hôpital Charles Nicolle

Rouen, , France

Site Status

Service de Cardiologie - CHU de Saint Etienne

Saint-Etienne, , France

Site Status

Service de Cardiologie - Hôpital de Hautepierre

Strasbourg, , France

Site Status

Service de Chirurgie Cardiovasculaire - Hôpital Rangueil

Toulouse, , France

Site Status

Service de Cardiologie B - Hôpital Trousseau

Tours, , France

Site Status

Département de Cardiologie - CHU de Nancy-Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

0203/076

Identifier Type: OTHER

Identifier Source: secondary_id

2007-A00888-45

Identifier Type: OTHER

Identifier Source: secondary_id

LOC/07-04

Identifier Type: OTHER

Identifier Source: secondary_id

35RC07_9901

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.